Societal Costs of Venous Thromboembolism and Subsequent Major Bleeding Events: A National Register-Based Study.
Detailed evidence on the societal costs of venous thromboembolism (VTE), i.e. deep vein thrombosis (DVT) and pulmonary embolism (PE), and of subsequent major bleeding events, e.g. intracranial and gastrointestinal bleedings, is limited. The objective was to estimate the average three-year societal event costs attributable to VTE and subsequent major bleedings in Denmark. Based on nationwide Danish registers, each incident patient diagnosed with VTE in the period from 2004 to 2016 was identified and matched with four non-VTE patients by nearest-neighbour propensity score matching. For bleeding patients, the reference cohort was VTE patients without bleedings. Event costs in terms of VTE, DVT, PE, and major bleedings in VTE patients were measured by the "difference-in-actual-cost" method within three years after the incidence. Societal costs included healthcare costs (primary care, hospital, prescription medicine), municipality home care services, and production loss.The study population included 74,137 VTE incident patients (DVT: 43,099; PE: 31,038), and 4,887 VTE patients with a major bleeding within three years from VTE diagnosis. The three-year attributable societal VTE event costs were 40,024 EUR (DVT: 34,509 EUR; PE: 50,083 EUR) with 53% of these costs appearing in the first incident year. Similar results for major bleedings were 51,168 EUR with 46% of these costs appearing in the first incident year. The societal costs of VTE and subsequent major bleedings are substantial and ought to be considered. Estimated costs of events may be informative in evaluating the impact of preventive interventions targeting VTE and subsequent major bleedings.